Display options
Cite
Zhang W, Huang RS, Dolan ME. Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med. 2008;2008(1):7-14doi: 10.2147/pgpm.s4341.
Zhang, W., Huang, R. S., & Dolan, M. E. (2008). Integrating Epigenomics into Pharmacogenomic Studies. Pharmacogenomics and personalized medicine, 2008(1), 7-14. https://doi.org/10.2147/pgpm.s4341
Zhang, Wei, et al. "Integrating Epigenomics into Pharmacogenomic Studies." Pharmacogenomics and personalized medicine vol. 2008,1 (2008): 7-14. doi: https://doi.org/10.2147/pgpm.s4341
Zhang W, Huang RS, Dolan ME. Integrating Epigenomics into Pharmacogenomic Studies. Pharmgenomics Pers Med. 2008 Nov;2008(1):7-14. doi: 10.2147/pgpm.s4341. PMID: 20622972; PMCID: PMC2901114.
Copy Download .nbib Format: NLM
Share it on

Pharmgenomics Pers Med. 2008 Nov;2008(1):7-14. doi: 10.2147/pgpm.s4341.

Integrating Epigenomics into Pharmacogenomic Studies.

Pharmacogenomics and personalized medicine

Wei Zhang, R Stephanie Huang, M Eileen Dolan

Affiliations

  1. Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.

PMID: 20622972 PMCID: PMC2901114 DOI: 10.2147/pgpm.s4341

Abstract

The goal of personalized medicine is to recommend drug treatment based on an individual's genetic makeup. Pharmacogenomic studies utilize two main approaches: candidate gene and whole-genome. Both approaches analyze genetic variants such as single nucleotide polymorphisms (SNPs) to identify associations with drug response. In addition to DNA sequence variations, non-genetic but heritable epigenetic systems have also been implicated in regulating gene expression that could influence drug response. The International HapMap Project lymphoblastoid cell lines (LCLs) have been used to study genetic determinants responsible for expression variation and drug response. Recent studies have demonstrated that common genetic variants, including both SNPs and copy number variants (CNVs) account for a substantial fraction of natural variation in gene expression. Given the critical role played by DNA methylation in gene regulation and the fact that DNA methylation is currently the most studied epigenetic system, we suggest that profiling the variation in DNA methylation in the HapMap samples will provide new insights into the regulation of gene expression as well as the mechanisms of individual drug response at a new level of complexity. Epigenomics will substantially add to our knowledge of how genetics explains gene expression and pharmacogenomics.

References

  1. Clin Cancer Res. 2007 Dec 1;13(23):7107-12 - PubMed
  2. Nat Biotechnol. 2000 Mar;18(3):243 - PubMed
  3. Ann Oncol. 2007 Sep;18(9):1429-30 - PubMed
  4. Environ Health Perspect. 2007 Sep;115(9):1264-70 - PubMed
  5. Expert Opin Pharmacother. 2008 May;9(7):1109-19 - PubMed
  6. Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):967-75 - PubMed
  7. Nat Genet. 2007 Oct;39(10):1217-24 - PubMed
  8. J Biol Chem. 2002 Jan 18;277(3):1897-905 - PubMed
  9. Hum Mutat. 2008 Apr;29(4):461-7 - PubMed
  10. Mol Cancer Ther. 2007 Oct;6(10):2807-15 - PubMed
  11. Am J Respir Crit Care Med. 2008 Mar 15;177(6):567-73 - PubMed
  12. Nature. 2004 May 27;429(6990):457-63 - PubMed
  13. Nat Genet. 2002 Jan;30(1):92-6 - PubMed
  14. Nat Rev Genet. 2004 Jun;5(6):446-55 - PubMed
  15. Ann Intern Med. 2006 Nov 21;145(10):749-57 - PubMed
  16. Nature. 2004 Aug 12;430(7001):743-7 - PubMed
  17. J Clin Oncol. 2008 Mar 1;26(7):1119-27 - PubMed
  18. Nat Genet. 2005 Aug;37(8):853-62 - PubMed
  19. Nat Biotechnol. 1999 Dec;17(12):1144 - PubMed
  20. J Clin Oncol. 2007 Oct 10;25(29):4519-21 - PubMed
  21. Nucleic Acids Res. 2002 Mar 1;30(5):e21 - PubMed
  22. Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 - PubMed
  23. Trends Genet. 1999 Jan;15(1):34-7 - PubMed
  24. Cancer Treat Rev. 2006 Jun;32(4):261-76 - PubMed
  25. Science. 1975 Jan 24;187(4173):226-32 - PubMed
  26. Am J Hum Genet. 2008 Mar;82(3):631-40 - PubMed
  27. Cancer. 2005 Nov 1;104(9):1789-93 - PubMed
  28. Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 - PubMed
  29. Cell Biophys. 1989 Aug-Oct;15(1-2):15-20 - PubMed
  30. Pharmacogenomics. 2008 May;9(5):489-92 - PubMed
  31. Hum Mol Genet. 2007 Oct 15;16 Spec No. 2:R226-32 - PubMed
  32. Nat Genet. 2007 Feb;39(2):226-31 - PubMed
  33. Development. 2007 Nov;134(22):3959-65 - PubMed
  34. Nat Rev Cancer. 2004 Apr;4(4):296-307 - PubMed
  35. Curr Mol Med. 2007 Feb;7(1):85-102 - PubMed
  36. Cancer Res. 2007 Dec 1;67(23):11335-43 - PubMed
  37. Nature. 2005 Oct 27;437(7063):1299-320 - PubMed
  38. Curr Med Chem. 2006;13(16):1859-76 - PubMed
  39. PLoS Genet. 2008 Mar 21;4(3):e1000032 - PubMed
  40. Clin Pharmacol Ther. 2007 Mar;81(3):328-45 - PubMed
  41. Metabolism. 2008 Jul;57(7 Suppl 1):S16-23 - PubMed
  42. Clin Adv Hematol Oncol. 2003 Sep;1(9):517-8, 531 - PubMed
  43. Biotechniques. 2003 Jul;35(1):146-50 - PubMed
  44. J Natl Cancer Inst. 2002 Jan 2;94(1):26-32 - PubMed
  45. Science. 2007 Feb 9;315(5813):848-53 - PubMed
  46. Pharmacogenomics. 2007 Sep;8(9):1159-68 - PubMed
  47. Oncol Rep. 2008 Feb;19(2):407-12 - PubMed
  48. Dis Markers. 2007;23(1-2):43-9 - PubMed
  49. Methods Mol Biol. 2005;291:399-414 - PubMed
  50. Mol Cancer Ther. 2008 Apr;7(4):935-43 - PubMed
  51. Genome Res. 2006 Mar;16(3):383-93 - PubMed
  52. Environ Health Perspect. 2006 Mar;114(3):A140-1 - PubMed
  53. Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63 - PubMed
  54. Cell. 2006 Sep 22;126(6):1189-201 - PubMed
  55. Science. 2001 Feb 16;291(5507):1304-51 - PubMed
  56. Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6788-95 - PubMed
  57. Cancer Res. 2007 Nov 15;67(22):10647-52 - PubMed
  58. Br J Cancer. 2008 May 6;98(9):1485-93 - PubMed
  59. Brief Funct Genomic Proteomic. 2002 Jul;1(2):139-50 - PubMed
  60. Cell. 2007 Feb 23;128(4):669-81 - PubMed
  61. Curr Top Med Chem. 2004;4(13):1423-31 - PubMed
  62. PLoS Biol. 2003 Dec;1(3):E82 - PubMed
  63. JAMA. 2008 Apr 2;299(13):1574-87 - PubMed
  64. PLoS Genet. 2008 Apr 11;4(4):e1000052 - PubMed
  65. JAMA. 1998 Apr 15;279(15):1200-5 - PubMed
  66. Nature. 2001 Feb 15;409(6822):860-921 - PubMed
  67. Bioinform Biol Insights. 2008;2:15-23 - PubMed
  68. Curr Opin Mol Ther. 2002 Dec;4(6):548-58 - PubMed
  69. Am J Hum Genet. 2000 Jan;66(1):279-92 - PubMed
  70. Curr Opin Plant Biol. 2007 Apr;10(2):142-8 - PubMed
  71. Clin Pharmacol Ther. 2007 Mar;81(3):321-2 - PubMed
  72. J Clin Oncol. 2004 Nov 15;22(22):4632-42 - PubMed
  73. J Mol Evol. 2007 Sep;65(3):207-14 - PubMed
  74. Mutat Res. 1998 Sep 20;405(2):179-91 - PubMed
  75. Br J Clin Pharmacol. 2006 Jul;62(1):35-46 - PubMed
  76. Hum Genomics. 2008 Sep;3(1):53-70 - PubMed
  77. PLoS Biol. 2004 Dec;2(12):e405 - PubMed
  78. Nature. 2003 Dec 18;426(6968):789-96 - PubMed
  79. Nat Genet. 2006 Dec;38(12):1378-85 - PubMed
  80. Pharmacogenomics. 2008 Feb;9(2):215-34 - PubMed
  81. Curr Opin Genet Dev. 2008 Feb;18(1):62-7 - PubMed
  82. J Clin Oncol. 2005 Aug 1;23(22):5007-18 - PubMed
  83. Nat Rev Genet. 2007 Aug;8(8):601-9 - PubMed
  84. Am J Hum Genet. 2008 May;82(5):1101-13 - PubMed
  85. Am J Hum Genet. 2007 Sep;81(3):427-37 - PubMed
  86. Nature. 2006 Nov 23;444(7118):444-54 - PubMed

Publication Types

Grant support